PRLog (Press Release) - Jun 05, 2012 - Immune Response BioPharma Inc. Posts First Half 2012 Results.
First Half 2012 Highlights Include
IRBP Granted Ownership of U.S. Patent 8,053,197, The King Patent Extends Intellectual Property Coverage into 2027 for the Treatment of Auto-Immune Diseases with TCR Vaccination & FOXP3+ Expression Technology.
Appointed Dr. Halina Offner to the Board of Directors, she brings a wealth of experience from OHSU in Neurology and Research involving the use of Estrogen with TCR Peptide Vaccination.
Initiated Plans for a Phase 3 RAVAX Clinical Trial for Rheumatoid Arthritis utilizing the TCR Peptide formulation with the addition of Estrogen Arm for increased results as over 70% of RA patients are women.
IRBP’s Flagship Multiple Sclerosis Vaccine Phase 2B Study NeuroVax vs Avonex Head to Head Study involving 200-500 patients receiving NeuroVax drug planning and partnership discussions underway with multiple big pharma partners continues.
Began discussions with Althea in San Diego, Ca for the manufacture of clinical grade NeuroVax for our planned Phase 2B Study.
IRBP has the NeuroVax IND in complete form ready to submit to the FDA for approval of the new Phase 2B study which will be lead by Dr. Bourdette of OHSU as lead clinical investigator who believe NeuroVax can become treatment of choice for MS patients.
IRBP Announced changes in the formulation of REMUNE to Weekly and Monthly Dosing, IRBP will delay work on the HIV/AIDS vaccine until funding is secured and then begin work on this program only after NeuroVax and RAVAX have been successfully partnered or we secure funding to develop the vaccines in house.
“IRBP had a very busy and exciting first half of 2012, we are pleased with our progress and look forward to a banner 2012. We continue to have an active and constructive dialogue with several big pharma potential partners for NeuroVax and we have begun discussions for the newly announced Phase 3 RAVAX study. We believe we have a great drug for multiple sclerosis and an equally competitive drug for RA, we will have the first MS and first RA vaccines to reach the market. IRBP will either partner the drugs or raise capital to develop the pipeline on our own, the best is yet to come.” IRBP CEO Mr. David Buswell
Immune Response BioPharma, Inc. maybe found on the WorldWide Web @ www.immuneresponsebiopharma.com
